- Product
- Korea’s first epidemiological report on COVID-19 deaths
- by Lee, in-bok Mar 31, 2020 06:29am
- A study analyzed deaths from COVID-19 in Korea and found male patients in 70s with chronic cardiac disorder like hypertension were critically affected. Apparently, most of them had died in average 10 days after the onset COVID-19 symptoms, and their average time to death was unaffected regardless of underlying illness. First epidemio
- Product
- Who will succeed in COVID-19 treatment?
- by choi-sun Mar 25, 2020 06:01am
- As pharmaceutical companies around the world are plunging into the development of vaccines and treatments for COVID-19 treatment, attention is focused on who will succeed in commercialization. Among the treatments, Gilead Sciences entered Phase III of clinical trials, and in the field of vaccines, it entered Phase I by Moderna Therapeutics. H
- Product
- CartiLife has passed 5 years follow-up result
- by choi. sun Mar 11, 2020 06:27am
- Domestic osteoarthritic treatment has shown positive results for bone repair in the long-term follow-up of five years. The results are encouraging, as the osteoarthritis treatments that have shown their intention to compete have failed to demonstrate 'Disease Modifying OestoArthritis Drugs' (DMOAD) that structurally inhibit disease progressio
- Product
- Panic buying Tylenol-Advil in fear of COVID-19 fake news
- by Jung, Heung-Jun Mar 4, 2020 06:27am
- Tylenol and Advil are out of stock as their demands have skyrocketed due to online fake news encouraging panic buying of OTC drugs and claiming the Korean government’s containment of COVID-19 has failed. On Mar. 2, a multiple online pharmacies have posted notice on shortage of Tylenol, Advil and Aspirin. Apparently, the circulating
- Product
- What drug will be replaced by Belviq’s withdrawal?
- by Lee, in-bok Feb 18, 2020 10:49am
- As Ildong’s Belviq, which dominated the obese drug market for a long time, is finally exiting the market, there is a growing interest in which drug will fill this gap. Obesity experts are predicting that safety-oriented prescriptions may be available for the time being, while Saxenda and Qsymia are expected to benefit directly. The Min
- Product
- Ebola drug Remdesivir is used to treat COVID-19
- by Lee, In-Bok Feb 13, 2020 06:28am
- Remdesivir by Gilead, which is being developed as an Ebola treatment, is expected to benefit significantly from the spread of COVID-19. The explosive demand for therapeutics around the world has led to unintended recruitment of clinical trials, which has resulted in significant time and cost savings. In some cases, the possibility of quick pe
- Product
- It costs ₩867 million to become a physician
- by Kang, Shin-Kook Feb 11, 2020 06:29am
- It is estimated that it costs &8361;867 million from entering medical school to obtaining professional qualification. The Korean Medical Association(KMA)'s research institute for healthcare policy (Director Deok-sun Ahn) announced on the 7th that it has published a research report on the estimation of doctor training costs and public support
- Product
- Lyxumia by Sanofi stops supply in the second half
- by Kim, Min-Gun Feb 10, 2020 06:31am
- Sanofi-Aventis Korea's supply of GLP-1 analog diabetes treatment ‘Lyxumia (Lixisenatide)’ will be discontinued from June this year. According to the distribution industry on the 7th, Sanofi recently announced that it has stopped supplying two formulations, such as 10μg and 20μg of Lyxumia pen, due to company circumstances. Sanofi sa
- Product
- Taltz for interleukin Psoriasis expands Rx Area in hospitals
- by Eo, Yun-Ho Jan 6, 2020 06:22am
- Lilly's interleukin IL-17A antagonist, Taltz, is settling on its prescription area at general hospitals. According to the related industry on the 6th, psoriasis treatment Taltz (Ixekizumab) passed the drug commitee (DC) of Seoul National Hospital recently after Asan Hospital and Severance Hospital among the Big Five. In addition, prescri
- Product
- Samsung completes Phase III of Lucentis Biosimilar
- by Lee, Seok-Jun Jan 2, 2020 06:08am
- Samsung Bioepis’ Lucentis Biosimilar (SB11)' phase III completed. Lucentis' global sales last year were about ￦4.2 trillion. Samsung Bioepis recently announced its last patient visit for the SB11 phase III trial was done. Phase III examined compared non-inferiority with the original Lucentis in a total of 705 patients with Wet Age
